drugset / Trial / NCT02169414

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

NCT02169414

Phase 1 Completed 74 enrolled Bial - Portela C S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in steady-state conditions on the levodopa pharmacokinetics of a single dose of immediate-release levodopa/carbidopa 100/25 mg and of a single dose of immediate-release levodopa/benserazide 100/25 mg.

Timeline

Start
2010-02
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 5 mg
Subject Opicapone Small molecule 15 mg
Subject Opicapone Small molecule 50 mg
Subject levodopa/benserazide Unknown
Subject levodopa/carbidopa Unknown

Indications